Britain and America have announced a significant bilateral deal that will preserve zero levies on UK pharmaceutical shipments being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost spending on drugs through the public health system. This move guarantees that tariffs on these key goods will stay at nothing for a timeframe of 36 months.
This development is in response to earlier warnings to dramatically increase duties on patented drug imports, with figures floated as high as 100%.
"This agreement with the Britain reinforces the global environment for innovative medicines and introduces long-overdue balance to U.S.–U.K. drug exports," a release declared.
Economic Impact
Pharmaceuticals represent one of the Britain's biggest export categories to the United States, which is easily the largest market for leading UK drugmakers.
Trade data show that in the year prior to last September, the UK shipped drugs worth £11.1bn to the US. This value represented a significant portion of total UK exports in that period.
"This deal safeguards jobs, stimulates funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key British Pledges
The pact involves several specific commitments from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to stay within budget will be restricted at 15%. Last year, repayments exceeded 20%.
Industry Background
The pact follows a ongoing row between the pharmaceutical industry and the UK government over spending levels and approval rates.
These tensions were exacerbated by claims that US patients were paying several times more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been paused or scrapped, while multi-billion-dollar expansions have been pledged toward US facilities.
One official stated that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a share of its overall budget over the past decade.
